IMU-201 is under clinical development by Imugene and currently in Phase I for Squamous Non-Small Cell Lung Cancer. According to GlobalData, Phase I drugs for Squamous Non-Small Cell Lung Cancer have an 89% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how IMU-201’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Vaccine is under development for the treatment of colorectal cancer, non-small cell lung cancer and breast cancer. The vaccine candidate is a B cell vaccine (mimotope peptide), which is similar to the structure of an epitope of a specific cancer antigen. It acts by targeting PD1. It is administered through lyophilized emulsion.
Imugene is a clinical-stage biopharmaceutical company that focuses on the development of vaccines in the area of oncology immune. The company develops immunotherapies that activate the immune system of cancer patients to identify and eradicate tumors. The company’s pipeline products include HER-Vaxx, PD1-Vaxx, B-Vaxx, Vaxinia (CF33-hNIS), CHECKvacc (CF33+ hNIS+ PD-L1), PD-L1, VEGF, IGF-1R, HER-1, and HER-3 for the treatment of various tumors including gastric, breast, lung cancers. Imugene’s lead product candidate, CF33 is a chimeric vaccinia poxvirus for the treatment of mixed advanced solid tumors (MAST) and metastatic triple-negative breast cancer. It develops vaccine candidates based on Mimotope technology, which uses peptide mimics of conformational epitopes recognized by an antibody with antitumor activity. Imugene is headquartered in Sydney, New South Wales Australia.
For a complete picture of IMU-201’s drug-specific PTSR and LoA scores, buy the report here.